None listed
Conditions
Brief summary
Immune dysfunction has been thought of to be involved in patients with chronic prostatitis. Thus we use xuanju compound capsule, a traditional chinese drug, to treat chronic prostatitis and terazosin used in control group. XUANJU capsule is a kind of chinese traditional drug and has the role in immunoregulation. If xuanju capsule indeed improve the symptom of patients with chronic prostatitis, will give strong evidence to demonstrate the important role of immune regulation in treatment of chronic prostatitis.
Interventions
xuanju compound capsule in treatment of chronic prostatitis; 1.26mg oral administrated 3 times daily for 12 weeks; keeping diary for taking medicine
Sponsors
zhou tie
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
Male
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
1.consistent with chronic non-bacterial prostatitis diagnosis, duration >3 months; 2.aged 18 to 50 years old; 3.Chronic Prostatitis Symptom Index (NIH-CPSI) >11 points; 4.immune dysfunction; (recommended results based on pre-select several sensitive indicators); 5.voluntarily signed informed consent.
Exclusion criteria
1.except for I,II, IV type of prostatitis patients; 2.pelvic area pain, voiding dysfunction patients, benign prostatic hyperplasia, prostate cancer, testicular epididymis and spermatic cord disease, overactive bladder, neurogenic bladder, interstitial cystitis, bladder gland , sexually transmitted diseases, bladder cancer, anorectal disease, lumbar disease, central and peripheral neuropathy; 3.local pain as the main manifestation of the patients, specifically by the ureteral stones, bladder stones, inguinal hernia, pubic inflammation, varicocele, epididymitis, colorectal disease, caused by low back myofascial go far; 4.severe neurosis, mental illness; 5.past month have used drugs for treating chronic prostatitis or other relevant treatment; 6.associated with cardiovascular, cerebrovascular, liver and kidney and hematopoietic system in patients with severe primary disease, liver function ALT and / or AST> 1.5 times the upper limit of normal persons; 7.allergies, or known of the test drug ingredients or terazosin drugs have allergies;; 8.participating in the other clinical trials in a past month; 9.researchers consider it inappropriate to participate in clinical trials.
Outcome results
None listed